Ulcerative colitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

  NCT07250815· Takeda· Updated 15 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Mirikizumab Real World Protocol

  NCT06696014· University of North Carolina, Chapel Hill· Updated 24 Sept 2026

  “Poor accrual”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  Prediction of Dietary Intervention Efficacy in Mild Ulcerative Colitis Patients Based on Fecal Microbiome Signatures

  NCT05579483· Wageningen University· Updated 20 Aug 2026

  “No funding”Registry text, quoted unchanged. Source

• Terminated

  Nicotinamide Riboside in Ulcerative Colitis

  NCT05561738· University of Pittsburgh· Updated 10 Aug 2026

  “This was a pilot study only. The primary goal of determining feasibility was achieved. Due to logistical issues and a desire to design a better trial, the study was terminated before reaching enrollment goals.”Registry text, quoted unchanged. Source

• Terminated

  A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

  NCT06681389· NIBEC Co., Ltd.· Updated 23 Jun 2026

  “Study was terminated at the end of Part A for strategic reasons (not due to lack of efficacy or safety issues”Registry text, quoted unchanged. Source

• Terminated

  Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis

  NCT07653750· University Hospital, Clermont-Ferrand· Updated 17 Jun 2026

  “We were able to test our hypothesis using the current data”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

  NCT05785715· AbbVie· Updated 15 Jun 2026

  “Sponsor Decision\_Not Safety Related”Registry text, quoted unchanged. Source

• Terminated

  VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT05156125· Oppilan Pharma Ltd· Updated 30 Apr 2026

  “The Induction and Long-Term Extension Periods were completed and analyzed as planned. The Sponsor decided to terminate clinical conduct in the Open-Label Extension Period. The decision to terminate the study was not due to safety concerns.”Registry text, quoted unchanged. Source

• Suspended

  Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

  NCT04225819· Massachusetts General Hospital· Updated 27 Apr 2026

  “Protocol is being modified.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates

  NCT07923383· Sanofi· Source

• MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease

  NCT06788340· Odense University Hospital· Source

• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Pfizer· Source

• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· Eli Lilly & Co.· Source

• A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Hoffmann-La Roche· Source

• A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis

  NCT07747480· GlaxoSmithKline· Source

• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Janssen Research & Development, LLC· Source

• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Eli Lilly and Company· Source

• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Eli Lilly and Company· Source

• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 89
• Genome-Wide Association Study 56

• Gut Microbiota, Inflammatory Bowel Disease and the Prioritization of Host Effector Genes: A Two-Sample Mendelian Randomization Study with Independent Replication, cis-eQTL Colocalization and Single-Cell Localization.

  Int J Mol Sci, Sept 2026

• Identification of Ferro-Aging-Related Biomarkers for Ulcerative Colitis Through Integrated Machine Learning, Single-Cell Analysis, and Spatial Transcriptomics.

  FASEB J, Sept 2026

• Shaoyao decoction inhibits neutrophil migration and restores epithelial integrity in ulcerative colitis model mice: insights from single-cell sequencing.

  Phytomedicine, Aug 2026

• Macrophage-Centered Integration of Single-Cell and Bulk Transcriptomic Data Identifies CCL3, CCL4, and JUNB as Inflammatory Regulatory Signatures in Ulcerative Colitis.

  Genes (Basel), Jul 2026

• Single-cell transcriptomic profiling identifies TIMP1 as a diagnostic marker linked to macrophage ferroptosis in ulcerative colitis.

  Tissue Cell, Jun 2026

• Identification and validation of platelet activation-related signatures in ulcerative colitis: a study based on machine learning and single-cell transcriptomic analysis.

  Front Immunol, Jun 2026

• Interleukin-8-driven monocyte activation in primary sclerosing cholangitis: Insights from single-cell analysis and humanized immune system mice.

  JHEP Rep, Jun 2026

• A single-cell atlas of ulcerative colitis reveals neutrophil-stromal circuits linked to biologic therapy resistance.

  Front Immunol, Jun 2026

• Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks.

  J Clin Invest, Jun 2026

• Multidimensional dissection of shared genetic susceptibility in ulcerative colitis and colorectal cancer: novel insights from integrative single-cell and multi-omics analysis.

  Inflamm Res, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.